Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10189856
APP PUB NO 20140038956A1
SERIAL NO

13816020

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ADVERIO PHARMA GMBHKAISER-WILHELM-ALLEE 1 51373 LEVERKUSEN 51373

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Follmann, Markus Wülfrath, DE 77 838
Hahn, Michael Langenfeld, DE 178 1373
Hirth-Dietrich, Claudia Wuppertal, DE 40 270
Knorr, Andreas Erkrath, DE 205 2708
Sandner, Peter Wuppertal, DE 36 120
Stasch, Johannes-Peter Solingen, DE 206 3335
Von, Degenfeld Georges Leverkusen, DE 25 122

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 29, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 29, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00